Vertex Pharmaceuticals: Pipeline Progression & Product Launches As A Substantial Catalysts For  Growth Trajectory! 

Vertex Pharmaceuticals demonstrated notable progress in its financial and operational performance for the fourth quarter and full year 2024. The company reported record revenues, attributed primarily to the sustained commercial success of its cystic fibrosis (CF) treatments and the initiation of CASGEVY’s launch. Vertex’s total product revenue for the fourth quarter reached $2.91 billion, marking a 16% increase from the prior year, while full-year revenues surpassed $11 billion, reflecting a 12% growth rate.